Trials / Completed
CompletedNCT03780517
Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors
A Phase 1 Study of BOS172738 in Patients With Advanced Solid Tumors With RET Gene Alterations Including Non-Small Cell Lung Cancer (NSCLC) and Medullary Thyroid Cancer (MTC)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 117 (actual)
- Sponsor
- Boston Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will be conducted to assess the safety and tolerability of BOS172738 when administered to patients with advanced solid tumors with rearranged during transfection (RET) gene alterations and also to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of BOS172738.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BOS172738 | Oral capsules |
Timeline
- Start date
- 2018-12-12
- Primary completion
- 2023-09-26
- Completion
- 2023-09-26
- First posted
- 2018-12-19
- Last updated
- 2023-10-30
Locations
21 sites across 7 countries: United States, Belgium, France, Hong Kong, South Korea, Spain, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03780517. Inclusion in this directory is not an endorsement.